Entinostat Application Scope

Entinostat (also known as Jingzhuda in China; code names MS-275, SNDX-275) is a selective class I histone deacetylase (HDAC) inhibitor primarily developed for use in oncology. It works by inhibiting HDAC enzymes, leading to hyperacetylation of histones and non-histone proteins, which modulates gene expression, promotes cell cycle arrest, and induces apoptosis in cancer cells. Its mechanism is not fully elucidated but involves epigenetic regulation to enhance antitumor effects, often in combination with other therapies.

entisistat tablets

Entinostat Characteristics

Ingredients: Entinostat
Properties: Entinostat is a histone deacetylase (HDAC) inhibitor used primarily in the treatment of certain cancers, particularly as a part of combination therapy for breast cancer. It works by modifying gene expression and has shown potential in enhancing immune responses.
Packaging Specification: Available in tablet form, typically in doses of 4 mg x 5 tablets
Storage: Store in a cool, dry place, away from moisture and heat. It is best kept at room temperature, around 20-25°C (68-77°F).
Expiry Date: Refer to packaging for specific expiration date.
Executive Standard: Manufactured following pharmaceutical quality standards.
Approval Number: The approval number varies by country and regulatory authority. Always refer to the local regulatory body for the correct number.
Date of Revision: Check with the packaging for the most current revision date.
Manufacturer: Taizhou EOC Pharma Co., Ltd. (Chinese trade name: 景助达 / Jing Zhuda).

Guidelines for the Use of Entinostat

Dosage and Administration:
- Recommended Dose: Typically, the dose is 5 mg once weekly or as prescribed by a healthcare professional.
- Administration: Entinostat is taken orally, usually in tablet form. It should be taken with or without food, but it is important to maintain consistency in how it is taken to avoid fluctuations in absorption.
- Missed Dose: If a dose is missed, take it as soon as possible unless it’s almost time for the next dose. Do not double the dose to make up for a missed one. Always follow the doctor’s instructions.
Adverse Reactions:
- Common Adverse Reactions:
  - Fatigue
  - Nausea
  - Decreased appetite
  - Vomiting
  - Diarrhea
- Serious Adverse Reactions:
  - Thrombocytopenia (low platelet count)
  - Anemia (low red blood cell count)
  - Liver function abnormalities
  - Serious infections
  - Shortness of breath
  - Severe allergic reactions (anaphylaxis)
Contraindications:
- Hypersensitivity or allergy to Entinostat or any of its components.
- Pregnant or breastfeeding women should avoid using Entinostat unless deemed necessary by a healthcare provider.
- People with significant liver or kidney impairments may need dosage adjustments or alternative treatments.
Precautions:
- Regular Monitoring: Regular blood tests (complete blood count, liver enzymes) are recommended to monitor for potential adverse effects such as cytopenias or liver dysfunction.
- Pregnancy Category: Category C (potential risk to the fetus; use only if the benefit outweighs the risk).
- Drug Interactions: Entinostat may interact with other drugs, particularly those metabolized by the liver (cytochrome P450 enzymes). Always inform your doctor of any other medications you are taking.

Entinostat Interactions

Cytochrome P450 Inhibitors or Inducers: Drugs like ketoconazole (an inhibitor) or rifampin (an inducer) can alter the metabolism of Entinostat.
Other Chemotherapy Agents: Using Entinostat in combination with other chemotherapy drugs can increase the risk of adverse reactions, especially concerning bone marrow suppression.
Anticoagulants: Increased risk of bleeding when combined with anticoagulant medications.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.